|
Market Closed -
NYSE
04:04:03 2026-10-21 pm EDT
|
Pre-market 07:00:15 am | |||
| 100.51 USD | -1.89% |
|
100.84 | +0.32% |
| 05:58am | Leerink Partners Adjusts Price Target on Abbott Laboratories to $106 From $109 | MT |
| 05:57am | BTIG Adjusts Price Target on Abbott Laboratories to $125 From $134 | MT |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 173,921 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -20.17% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 194,854 | 194,599 | 190,950 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -12.33% | -0.13% | -1.88% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 29.6x | 22.9x | 20.2x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 4.37x | 3.49x | 3.32x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -3.41x | 0.8x | 1.5x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.47x | 3.22x | 3.03x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 3.89x | 3.6x | 3.32x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 15.4x | 13.6x | 12.2x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 16.7x | 15.1x | 13.6x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 25.9x | 21.8x | 20.1x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.86% | 4.58% | 4.97% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.571 | 2.741 | 2.899 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.56% | 2.73% | 2.88% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.397 | 4.387 | 4.983 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 75.7% | 62.5% | 58.2% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,059 | 54,060 | 57,471 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 12,648 | 14,347 | 15,599 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,683 | 12,887 | 14,034 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,123 | 7,771 | 8,582 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 20,933 | 20,678 | 17,030 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 100.51 | 100.51 | 100.51 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,730,383 | - | - |
| Announcement Date | 1/26/22 | 1/25/23 | 1/24/24 | 1/22/25 | 1/22/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 29.59x | 3.89x | 15.41x | 2.56% | 174B | |
| 23.21x | 4.54x | 15.84x | 1.21% | 114B | |
| 19.89x | 3.46x | 12.4x | 3.05% | 114B | |
| 30.39x | 2.95x | 11.92x | 2.36% | 89.64B | |
| 18.67x | 0.21x | 13.47x | 0.7% | 64.96B | |
| 31.91x | 8x | 20.56x | 1.24% | 56.09B | |
| 38.54x | 3.57x | 12.15x | 2.04% | 52.94B | |
| 37.48x | 9.31x | 26.04x | -.--% | 43.6B | |
| 39.32x | 3.19x | 11.88x | 0.55% | 32.77B | |
| 47.44x | 1.31x | 12.13x | 0.21% | 30.98B | |
| Average | 31.64x | 4.04x | 15.18x | 1.39% | 77.29B | |
| Weighted average by Cap. | 28.75x | 3.96x | 14.93x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
